Skip to main content

Table 1 Summary of clinical trials using CAR T cell mesothelin-targeted immunotherapies in various solid tumor

From: Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

Target Intervention Phase Treated Cancers Primary outcome measures Clinical Trials Identifier Status
Mesothelin CAR T cells alone I Metastatic pancreatic ductal adenocarcinoma (PDAC) Number of adverse events NCT01897415 Completed (Well-tolerated and showed preliminary evidence of antitumor efficacy in pancreatic cancer)
CAR T cells + fludarabine, cyclophosphamide & aldeslekin I/II Metastatic cancers (PDAC, cervical, lung, ovarian & mesothelioma) Frequency and severity of adverse events & objective response rate (ORR) NCT01583686 Recruiting
CAR T cells with/without cyclophosphamide I Unresectable/ Metastatic PDAC Number of participants with adverse events NCT03323944 Active, not recruiting
CAR T cells with/without cyclophosphamide I Metastatic PDAC, epithelial ovarian cancer, & mesothelioma Number of adverse events NCT02159716 Completed
(No acute adverse events were observed)
CEA Anti-CEA CAR-T cells Ib Liver metastases Number of participants with adverse events NCT02850536 Active, not recruiting
II Metastatic colorectal cancer Number of participants with adverse events NCT02959151 Recruiting
I Lung cancer
Colorectal cancer
Gastric cancer
Breast cancer
PDAC
Toxicity profile and number of participants with adverse events NCT02349724 Recruiting
I PDAC Number of patients with tumor response NCT03267173 Recruiting
MUC-1 Anti-MUC-1 CAR T cells I/II Hepatocellular carcinoma
Non-small cell lung cancer
PDAC
Triple-negative invasive breast cancer
Adverse events associated with the administration of anti-MUC-1 CAR T cells NCT02587689 Recruiting
I/II Malignant glioma of brain
Colorectal cancer
Gastric cancer
Adverse events associated with the administration of anti-MUC-1 CAR T cells NCT02617134 Recruiting
Anti-CTLA-4/PD-1 expressing MUC1-CAR-T cells I/II Advanced solid tumor Safety profile of CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells NCT03179007 Recruiting
FAP Adoptive transfer of re-directed FAP-specific T cells I Malignant pleural mesothelioma Safety profile NCT01722149 Active, not recruiting